RT Journal Article
SR Electronic
T1 Is acetazolamide a potential intervention for people with bipolar disorders? A scoping review protocol
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.08.27.22279292
DO 10.1101/2022.08.27.22279292
A1 Rebecca Strawbridge
A1 Stelios Orfanos
A1 Nefize Yalin
A1 Allan H Young
YR 2022
UL http://medrxiv.org/content/early/2022/08/30/2022.08.27.22279292.abstract
AB Acetazolamide is a carbonic anhydrase inhibitor whose primary indication is to alleviate altitude sickness, but it is also used in the treatment of glaucoma, seizures and oedema. Although it has not been repurposed for psychiatric illnesses, acetazolamide has been advocated for its putative benefits in those with a bipolar disorder (BD). Because current treatment options for BD bring a variety of challenges, it is important to examine the current evidence to date in a formal synthesis. This article describes a protocol for a scoping review to do so, in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for scoping reviews (PRISMA-ScR). PubMed, Embase and PsycInfo will be searched for all available publications focusing on the intervention acetazolamide for people with BD. This will include non-primary and primary research of any design, focusing on any outcome, in order to comprehensively bring together the work that has been undertaken to date on this topic. Relevant data from included articles will be subject to a narrative synthesis. It is anticipated that the results from the review will help to ascertain the potential for acetazolamide to benefit people with bipolar affective disorders in the future and aid the planning of future primary research to establish this.Competing Interest StatementIn the last 36 months, RS declares an honorarium from Janssen. AHY declares the following: honoraria for speaking from Astra Zeneca, Lundbeck, Eli Lilly, Sunovion, honoraria for consulting from Allergan, Livanova and Lundbeck, Sunovion, Janssen, and research grant support from Janssen. NY has worked on studies conducted together with Janssen Cliag, Corcept Therapeutics and COMPASS Pathways. SO has no conflict of interest to declare.Funding StatementThis work is supported by the National Institute for Health & Care Research (NIHR) Maudsley Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData produced in this study will be available upon reasonable request to the authors.